E&G Advisors LP Decreases Position in Gilead Sciences, Inc. (NASDAQ:GILD)

E&G Advisors LP cut its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 2.2% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 17,429 shares of the biopharmaceutical company’s stock after selling 400 shares during the period. E&G Advisors LP’s holdings in Gilead Sciences were worth $1,610,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in GILD. Bellevue Group AG raised its position in shares of Gilead Sciences by 18.2% in the third quarter. Bellevue Group AG now owns 46,027 shares of the biopharmaceutical company’s stock valued at $3,859,000 after purchasing an additional 7,093 shares during the period. Quantinno Capital Management LP lifted its holdings in shares of Gilead Sciences by 149.5% in the third quarter. Quantinno Capital Management LP now owns 81,620 shares of the biopharmaceutical company’s stock worth $6,843,000 after buying an additional 48,910 shares in the last quarter. IRON Financial LLC bought a new position in shares of Gilead Sciences in the third quarter valued at approximately $830,000. Capital Investment Advisors LLC grew its stake in Gilead Sciences by 2.6% during the fourth quarter. Capital Investment Advisors LLC now owns 387,492 shares of the biopharmaceutical company’s stock valued at $35,793,000 after acquiring an additional 9,791 shares in the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in Gilead Sciences by 12.9% during the 3rd quarter. Wealth Enhancement Advisory Services LLC now owns 323,011 shares of the biopharmaceutical company’s stock worth $27,081,000 after acquiring an additional 36,895 shares during the period. Institutional investors own 83.67% of the company’s stock.

Gilead Sciences Price Performance

Shares of GILD stock opened at $98.38 on Tuesday. Gilead Sciences, Inc. has a 12 month low of $62.07 and a 12 month high of $99.45. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.26 and a quick ratio of 1.10. The company has a market capitalization of $122.61 billion, a PE ratio of 1,093.11, a price-to-earnings-growth ratio of 1.37 and a beta of 0.18. The firm’s 50-day moving average is $92.42 and its two-hundred day moving average is $85.96.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.44. Gilead Sciences had a return on equity of 29.00% and a net margin of 0.45%. The company had revenue of $7.55 billion for the quarter, compared to analysts’ expectations of $7.01 billion. During the same period in the prior year, the firm earned $2.29 earnings per share. The firm’s revenue was up 7.0% compared to the same quarter last year. Analysts predict that Gilead Sciences, Inc. will post 4.34 earnings per share for the current year.

Insider Transactions at Gilead Sciences

In other news, insider Merdad Parsey sold 25,590 shares of the business’s stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, CFO Andrew D. Dickinson sold 248,645 shares of the stock in a transaction dated Friday, November 29th. The stock was sold at an average price of $92.76, for a total value of $23,064,310.20. Following the transaction, the chief financial officer now owns 138,919 shares in the company, valued at $12,886,126.44. This trade represents a 64.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 598,414 shares of company stock valued at $55,953,200. 0.29% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on GILD shares. Daiwa America upgraded Gilead Sciences to a “hold” rating in a research report on Monday, November 18th. Citigroup assumed coverage on Gilead Sciences in a report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Oppenheimer boosted their price objective on Gilead Sciences from $105.00 to $115.00 and gave the stock an “outperform” rating in a report on Tuesday, December 10th. BMO Capital Markets raised their target price on shares of Gilead Sciences from $94.00 to $102.00 and gave the company an “outperform” rating in a research note on Thursday, November 7th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a report on Wednesday, December 11th. Eleven investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $98.39.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.